In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants.

Related Links:

Publication date: Available online 9 August 2018Source: Journal of the Chinese Medical AssociationAuthor(s): Chien-Ting Chen, Jyh-Pyng Gau, Jing-Hwang Liu, Tzeon-Jye Chiou, Liang-Tsai Hsiao, Yao-Chung LiuAbstractBackgroundAcute lymphoblastic leukemia (ALL) remains one of the most difficult-to-cure hematological malignancies. Allogeneic hematopoietic stem cell transplantation (HSCT) provides curative potential but a substantial proportion of patients eventually will relapse. It is unknown if there are any modifiable factors exists that could improve survival or predict relapse immediately after HSCT is unknown. The aim of t…

AbstractThe intravenous CD22-directed antibody drug conjugate inotuzumab ozogamicin (Besponsa®) is approved in several countries including in the USA, EU and Japan, as monotherapy for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukaemia (ALL). In adults with relapsed/refractory B-cell ALL who had received one or two prior treatment regimens, inotuzumab ozogamicin was associated with significantly higher rates of complete remission (including complete remission with incomplete haematological recovery) [CR/CRi] than standard therapy in the pivotal INO-VATE ALL trial. Inotuzumab ozogamicin…

Source: Targeted OncologyCategory: Cancer & Oncology Source Type: research

Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ, Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network
Abstract
In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which …

Source: Clinical Lymphoma and MyelomaCategory: Cancer & Oncology Authors: Tags: Nat Rev Clin Oncol Source Type: research

z M, Alousi A, Couriel D, Pidala J, Arora M, Cutler C
Abstract
Upper gastrointestinal acute graft-versus-host disease is reported in approximately 30% of hematopoietic stem cell transplant recipients developing acute graft-versus-host disease. Currently classified as Grade II in Consensus criteria, upper gastrointestinal acute graft-versus-host disease is often treated with systemic immunosuppression. We reviewed the Center for International Blood and Marrow Transplant Research database to assess prognostic implications of upper gastrointestinal acute graft-versus-host disease in isolation or with other acute graf…

Source: HaematologicaCategory: Hematology Authors: Tags: Haematologica Source Type: research

This article emphasizes the specific pediatric aspects of long-term aftercare following myeloablative HSCT and provides an organ-based overview that covers main clinical patterns, incidence, and risk factors enhanced by current references and screening guidelines.Recent FindingsIn the last years, several attempts were made to separate pediatric outcome data from findings in adults. It turned out that not only the indication for but also the time and the procedures of HSCT substantially differ. Nearly any organ might be affected after the complex transplantation process and includes endocrinopathies, musculoskeletal disorde…

Contributors : H élène Royo ; Vaia Stavropoulou ; Jürg Schwaller ; Antoine M PetersSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe t(11;19)(q23;p13.3) translocation leading to the expression of an MLL-ENL fusion is one of the most prevalent alterations affecting the mixed lineage leukemia 1 (MLL1) gene, mostly associated with B-cell acute lymphoblastic leukemia (ALL). Using a doxycycline (DOX)-inducible transgenic mouse model ( “iMLL-ENL”) we show that direct induction or induction following transplantation of hematopoietic stem cells (HSC) but not o…

Source: GEO: Gene Expression OmnibusCategory: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research

CONCLUSIONS: Holistic patient support-specific activities and adapted protocols made a measurable impact on patient outcomes. High survival outcomes of patients have been achieved despite relatively few receiving salvage therapies or stem cell transplant.

Source: Indian Journal of CancerCategory: Cancer & Oncology Authors: Source Type: research

Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) are recognized as a unique population with specific characteristics and needs. In adolescents age 15 to 20 years, the use of fully pediatric protocols is supported by many comparative studies of pediatric and adult cooperative groups. In young adults, growing evidence suggests that pediatric-inspired or even fully pediatric approaches may also dramatically improve outcomes, leading to long-term survival rates of almost 70%, despite diminishing indications of hematopoietic stem-cell transplantation. In the last decade, better knowledge of the …

Source: BloodCategory: Hematology Authors: Tags: Pediatric Hematology, Lymphoid Neoplasia, Review Articles, Review Series, Clinical Trials and Observations Source Type: research

Authors: Corella Aznar EG, Ayerza Casas A, Carboné Bañeres A, Calvo Escribano MÁC, Labarta Aizpún JI, Samper Villagrasa P
Abstract
BACKGROUND: Survival of childhood acute lymphoblastic leukaemia involves an increasing risk of long-term morbidities. Due to the impact of cancer treatment and comorbidities, AL survivors may experience a decrease in their health-related quality of life.
OBJECTIVE: We aimed to describe the long-term comorbidities, related quality of life and their development predictors in these survivors.
METHODS: cross-sectional study of 54 survivors aged ≥18 and…

Source: Medicina ClinicaCategory: General Medicine Tags: Med Clin (Barc) Source Type: research

Eliminating high toxicity, invasive treatments like chemotherapy and stem cell transplant is a goal of acute lymphoblastic leukemia (ALL) research. Here, Oliver Ottmann, MD, FRCPath, of Cardiff Univer…


Author: VJHemOnc
Added: 07/18/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image